The natural history of recently diagnosed autonomic neuropathy over a period of 2 years

Diabetes Research and Clinical Practice

Volumn 42, Issue 1, 1998, Pages 55-63

  Karamitsos, D T ^a   Didangelos, T P ^a   Athyros, V G ^a   Kontopoulos, A G ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Diabetic autonomic neuropathy; Heart rate variability; Natural history

Indexed keywords

ADULT; ARTICLE; AUTONOMIC NEUROPATHY; CLINICAL ARTICLE; DIABETES MELLITUS; DIABETIC NEUROPATHY; DISEASE COURSE; FEMALE; FUNCTION TEST; HEART RATE VARIABILITY; HUMAN; MALE;

ADULT; AGED; ANALYSIS OF VARIANCE; AUTONOMIC NERVOUS SYSTEM DISEASES; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; FEMALE; FOLLOW-UP STUDIES; HEART RATE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RESPIRATORY MECHANICS; TIME FACTORS; VALSALVA MANEUVER;

EID: 0032193647     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(98)00089-8     Document Type: Article

References (25)

1. Sampson M.J., Wilson S., Karagiannis P., Edmonds M., Watkins P.J. Progression of diabetic autonomic neuropathy over a decade in insulin-dependent diabetics. Q. J. Med. 278:1990;635-646.
2. Ewing D.J., Campbell I.W., Clarke B.F. The natural history of diabetic autonomic neuropathy. Q. J. Med. 193:1980;95-108.
3. O'Brien I.A., McFadden J.P., Corrall R.J.M. The influence of diabetic autonomic neuropathy on mortality in insulin-dependent diabetics. Q. J. Med. 290:1991;495-502.
4. The Diabetes Control and Complications Trial Research Group, The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann. Intern. Med. 122 (1995) 561-568.
5. Ohkubo Y., Kishikawa H., Araki E., Miyata T., Isami S., Motoyoshi S., Kojima Y., Furuyoshi N., Shichiri M. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res. Clin. Pract. 28:1995;103-117.
6. Yagihashi S. Pathology and pathogenetic mechanisms of diabetic neuropathy. Diabetes Metab. Rev. 11:1995;193-225.
7. Consensus Statement, Report and Recommendations of the San Antonio Conference on Diabetic Neuropathy. Diabetes 37 (1988) 1000-1004.
8. Levitt N.S., Stansberry K.B. The natural progression of autonomic neuropathy and autonomic function tests in a cohort of people with IDDM. Diabetes Care. 19:1996;751-754.
9. Navarro X., Kennedy W.R., Sutherland D.E. Autonomic neuropathy and survival in diabetes mellitus: effects of pancreas transplantation. Diabetologia. 34(Suppl. 1):1991;108S-112S.
10. Quardi R., Ponzani P., Zanone M., Maule S., La Grotta A., Papotti G., Valentini M., Matteoda C., Chiandussi L., Fonzo D. Changes in autonomic nervous function over a period of 5 years in non-insulin-dependent diabetic patients. Diabetic Med. 10:1993;916-919.
11. The American Diabetes Association and the American Academy of Neurology, Consensus statement: standarized measures in diabetic neuropathy. Diabetes Care 18 (Suppl. 1) (1995) 59S-82S.
12. Ziegler D. Diabetic cardiovascular autonomic neuropathy: prognosis, diagnosis and treatment. Diabetes Metab. Rev. 10:1994;339-383.
13. Ziegler D., Laux G., Dannehl K., Spuler M., Muhlen H., Mayer P., Gries F.A. Assessment of cardiovascular autonomic function: age-related normal ranges and reproducibility of spectral analysis, vector analysis and standard tests of heart rate variation and blood pressure responses. Diabetic Med. 9:1992;166-175.
14. Kontopoulos A., Athyros V., Papageorgiou A., Avramidis M., Papadopoulos G., Boudoulas H. Effect of quinapril or metoprolol on heart rate variability in post-myocardial infarction patients. Am. J. Cardiol. 77:1996;242-246.
15. M. Jungsblut, Erfassung and analyse der herzfrequenzvariabilitat auf basis des Langzeit-EKG-Systems. Thesis, Hamburg, 1993.
16. Lombardi F., Sandrone G., Pernpruner S., Sala R., Garimoldi M., Cerutti S. Heart rate variability as an index of sympathovagal interaction after acute myocardial infarction. Am. J. Cardiol. 60:1987;1239-1245.
17. Spallone V., Uccioli L., Menzinger G. Diabetic autonomic neuropathy. Diabetes Metab. Rev. 11:1995;227-257.
18. Fagius J., Brattberg A., Jameson S., Berne C. Limited benefit of treatment of diabetic polyneuropathy with an aldose reductase inhibitor: a 24-week controlled trial. Diabetologia. 28:1985;323-329.
19. Green A., Jaspan J., Kavin H., Chung S., Schoenberg H. Influence of long-term aldose reductase inhibitor therapy on autonomic dysfunction of urinary bladder, stomach and cardiovascular systems in diabetic patients. Diabetes Res. Clin. Pract. 4:1987;67-75.
20. Pitts N.E., Vreeland F., Shaw G.L., Peterson M.J., Mehta D.J., Collier J., Gundersen K. Clinical experience with sorbinil-an aldose reductase inhibitor. Metabolism. 35(Suppl 1):1986;96S-100S.
21. Sundkvist G., Armstrong F.M., Bradbury J.E., Chaplin C., Ellis S.H., Owens D.R., Rosen I., Sonksen P. Peripheral and autonomic nerve function in 259 diabetic patients with peripheral neuropathy treated with ponalrestat (an aldose reductase inhibitor) or placebo for 18 months. J. Diabetes Complications. 6:1992;123-130.
22. Gill J.S., Williams G., Ghatei M.A., Hetreed A.H., Mather H.M., Bloom S.R. Effect of the aldose reductase inhibitor, ponalerstat, on diabetic neuropathy. Diabéte Métab. 16:1990;296-302.
23. Ziegler D., Mayer P., Rathman W., Gries F.A. 1-year treatment with aldose reductase inhibitor, ponalrestat, in diabetic neuropathy. Diabetes Res. Clin. Pract. 14:1991;63-74.
24. Giugliano D., Acampora R., Marfella R., Di Mario G., De Rosa N., Misso L., Ceriello A., Quatraro A., D'Onofrio F. Tolrestat in the primary prevention of diabetic neuropathy. Diabetes Care. 18:1995;536-541.
25. Giugliano D., Marfella R., Quatraro A., De Rosa N., Salvatore T., Cozzolino D., Ceriello A., Torella R. Tolrestat for mild diabetic neuropathy. A 52-week, randomized, placebo-controlled trial. Ann. Intern. Med. 118:1993;7-11.